Please assess the completion status of the following clinical trial:

Trial Title: Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) not curable by local therapy~* No prior systemic therapy for SCCHN in the recurrent or metastatic setting (with the exception of systemic therapy completed \> 6 months prior if given as part of multimodal treatment for locally advanced disease)~* Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx. Patients may not have a primary tumor site of upper esophagus, salivary gland, or nasopharynx (any histology)~* Availability of formalin-fixed, paraffin embedded tumor specimen or contemporary biopsy for immunohistochemical evaluation of pharmacodynamic markers of interest~* Willing to consent for baseline and on-treatment biopsy.~* Performance status 0 or 1~* Life expectancy of 6 months or more~* Adequate end organ function~* At least one radiographically measurable lesion~* PD-L1 expression level that is either~  1. Positive (combined positive score \[CPS\] ≥ 1) for the retifanlimab cohort, or~ 2. Negative (CPS \< 1) for the tebotelimab cohort~* Results available from human papilloma virus p16 status for oropharyngeal cancer~* Acceptable laboratory results~Exclusion Criteria:~* Disease suitable for local therapy administered with curative intent~* Progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced SCCHN~* Radiation or other non-systemic therapy within 2 weeks prior to the first dose of study drug~* Prior therapy with an anti-B7-H3, anti-PD-1, anti-PD-L1, or anti-LAG-3 agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Retifanlimab Cohort (Type: EXPERIMENTAL): Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles
- Tebotelimab Cohort (Type: EXPERIMENTAL): Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).